{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:45:06Z","timestamp":1770464706464,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-023-02936-1","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T06:01:56Z","timestamp":1706421716000},"page":"418-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-5952","authenticated-orcid":false,"given":"Emily","family":"Abdelmessih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-4124","authenticated-orcid":false,"given":"Tania","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Wo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Sango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-5010","authenticated-orcid":false,"given":"Elaine","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"issue":"3","key":"2936_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","volume":"89","author":"LC Marras","year":"2000","unstructured":"Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89(3):640\u2013646. https:\/\/doi.org\/10.1002\/1097-0142(20000801)89:3%3c640::AID-CNCR20%3e3.0.CO;2-E","journal-title":"Cancer"},{"issue":"2","key":"2936_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","volume":"22","author":"E Donnellan","year":"2017","unstructured":"Donnellan E, Khorana AA (2017) Cancer and venous thromboembolic disease: a review. Oncologist 22(2):199\u2013207. https:\/\/doi.org\/10.1634\/theoncologist.2016-0214","journal-title":"Oncologist"},{"key":"2936_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.07.138","volume":"269","author":"MC Vedovati","year":"2018","unstructured":"Vedovati MC, Giustozzi M, Verdecchia P et al (2018) Patients with cancer and atrial fibrillation treated with doacs: a prospective cohort study. Int J Cardiol 269:152\u2013157. https:\/\/doi.org\/10.1016\/j.ijcard.2018.07.138","journal-title":"Int J Cardiol"},{"issue":"20","key":"2936_CR4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034","journal-title":"J Clin Oncol"},{"issue":"17","key":"2936_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","journal-title":"N Engl J Med"},{"issue":"7","key":"2936_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, Van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"issue":"5","key":"2936_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461","journal-title":"J Clin Oncol"},{"issue":"6","key":"2936_CR8","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB et al (2021) Antithrombotic therapy for VTE disease. Chest 160(6):e545\u2013e608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055","journal-title":"Chest"},{"issue":"10","key":"2936_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2021.0047","volume":"19","author":"MB Streiff","year":"2021","unstructured":"Streiff MB, Holmstrom B, Angelini D et al (2021) Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 19(10):1181\u20131201. https:\/\/doi.org\/10.6004\/jnccn.2021.0047","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2936_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.7843","author":"D Schrag","year":"2023","unstructured":"Schrag D, Uno H, Rosovsky R et al (2023) Direct oral anticoagulants vs low-molecular-weight heparin and recurrent vte in patients with cancer: a randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2023.7843","journal-title":"JAMA"},{"issue":"7","key":"2936_CR11","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334\u2013e347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00160-7","journal-title":"Lancet Oncol"},{"issue":"16","key":"2936_CR12","doi-asserted-by":"publisher","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","volume":"7","author":"CL Fanola","year":"2018","unstructured":"Fanola CL, Ruff CT, Murphy SA et al (2018) Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 7(16):e008987. https:\/\/doi.org\/10.1161\/JAHA.118.008987","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2936_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","volume":"130","author":"C Melloni","year":"2017","unstructured":"Melloni C, Dunning A, Granger CB et al (2017) Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med 130(12):1440-1448.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2017.06.026","journal-title":"Am J Med"},{"issue":"1","key":"2936_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11239-017-1558-1","volume":"45","author":"E Xiang","year":"2018","unstructured":"Xiang E, Ahuja T, Raco V, Cirrone F, Green D, Papadopoulos J (2018) Anticoagulation prescribing patterns in patients with cancer. J Thromb Thrombolysis 45(1):89\u201398. https:\/\/doi.org\/10.1007\/s11239-017-1558-1","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2936_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/jth.14336","volume":"17","author":"BJ Carney","year":"2019","unstructured":"Carney BJ, Uhlmann EJ, Puligandla M et al (2019) Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 17(1):72\u201376. https:\/\/doi.org\/10.1111\/jth.14336","journal-title":"J Thromb Haemost"},{"issue":"24","key":"2936_CR16","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1182\/bloodadvances.2020003238","volume":"4","author":"A Leader","year":"2020","unstructured":"Leader A, Hamuly\u00e1k EN, Carney BJ et al (2020) Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv 4(24):6291\u20136297. https:\/\/doi.org\/10.1182\/bloodadvances.2020003238","journal-title":"Blood Adv"},{"issue":"5","key":"2936_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/onco.13698","volume":"26","author":"AW Swartz","year":"2021","unstructured":"Swartz AW, Drappatz J (2021) Safety of direct oral anticoagulants in central nervous system malignancies. Oncologist 26(5):427\u2013432. https:\/\/doi.org\/10.1002\/onco.13698","journal-title":"Oncologist"},{"key":"2936_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2021.10.023","volume":"208","author":"A Lee","year":"2021","unstructured":"Lee A, Oley F, Lo M et al (2021) Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. Thromb Res 208:148\u2013155. https:\/\/doi.org\/10.1016\/j.thromres.2021.10.023","journal-title":"Thromb Res"},{"issue":"1","key":"2936_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 3(1):1\u2013150","journal-title":"Kidney Int Suppl."},{"issue":"2","key":"2936_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 137(2):263\u2013272. https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest"},{"issue":"2","key":"2936_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"issue":"4","key":"2936_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2936_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease. Chest 149(2):315\u2013352. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026","journal-title":"Chest"},{"key":"2936_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H et al (2019) AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. https:\/\/doi.org\/10.1161\/CIR.0000000000000665","journal-title":"Circulation"},{"issue":"21","key":"2936_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS et al (2014) 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 64(21):e1\u2013e76. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2936_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/rth2.12377","volume":"4","author":"BJ Carney","year":"2020","unstructured":"Carney BJ, Uhlmann EJ, Puligandla M et al (2020) Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism. Res Pract Thromb Haemost 4(5):860\u2013865. https:\/\/doi.org\/10.1002\/rth2.12377","journal-title":"Res Pract Thromb Haemost"},{"issue":"16","key":"2936_CR27","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","volume":"6","author":"M Giustozzi","year":"2022","unstructured":"Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandal\u00e0 M (2022) ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 6(16):4873\u20134883. https:\/\/doi.org\/10.1182\/bloodadvances.2022008086","journal-title":"Blood Adv"},{"issue":"8","key":"2936_CR28","doi-asserted-by":"publisher","first-page":"107243","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107243","volume":"32","author":"J Yang","year":"2023","unstructured":"Yang J, He Z, Li M, Hong T, Ouyang T (2023) Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: a meta-analysis. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 32(8):107243. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2023.107243","journal-title":"J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc"},{"key":"2936_CR29","doi-asserted-by":"publisher","unstructured":"Santiago RB, Shah N, Ali A, Ranjan S. Safety of Direct Oral Anticoagulants as Compared to Low Molecular Weight Heparin in Treating Venous Thromboembolism in Patients with Primary Brain Tumors and Brain Metastases \u2013 A Review of Literature and Meta-analysis (S17.005). In: Monday, April 24. Lippincott Williams & Wilkins. 2023 doi:https:\/\/doi.org\/10.1212\/WNL.0000000000203961","DOI":"10.1212\/WNL.0000000000203961"},{"issue":"10","key":"2936_CR30","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907. https:\/\/doi.org\/10.1182\/blood-2007-10-116327","journal-title":"Blood"},{"key":"2936_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.thromres.2023.04.009","volume":"226","author":"A Cohen","year":"2023","unstructured":"Cohen A, Noxon V, Dhamane A et al (2023) Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer. Thromb Res 226:117\u2013126. https:\/\/doi.org\/10.1016\/j.thromres.2023.04.009","journal-title":"Thromb Res"},{"key":"2936_CR32","doi-asserted-by":"publisher","unstructured":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023. doi:https:\/\/doi.org\/10.1111\/jgs.18372","DOI":"10.1111\/jgs.18372"},{"issue":"1","key":"2936_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12959-020-00247-6","volume":"18","author":"B Setiawan","year":"2020","unstructured":"Setiawan B, Permatadewi CO, de Samakto B et al (2020) Von willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy. Thromb J 18(1):33. https:\/\/doi.org\/10.1186\/s12959-020-00247-6","journal-title":"Thromb J"},{"issue":"3","key":"2936_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/rth2.12197","volume":"3","author":"HL Obermeier","year":"2019","unstructured":"Obermeier HL, Riedl J, Ay C et al (2019) The role of ADAMTS-13 and von willebrand factor in cancer patients: results from the vienna cancer and thrombosis study. Res Pract Thromb Haemost 3(3):503\u2013514. https:\/\/doi.org\/10.1002\/rth2.12197","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"2936_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","volume":"69","author":"JU Doherty","year":"2017","unstructured":"Doherty JU, Gluckman TJ, Hucker WJ et al (2017) 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the american college of cardiology clinical expert consensus document task force. J Am Coll Cardiol 69(7):871\u2013898. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.024","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2936_CR36","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/neuonc\/noac125","volume":"24","author":"L Reed-Guy","year":"2022","unstructured":"Reed-Guy L, Desai AS, Phillips RE et al (2022) Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study. Neuro-Oncol 24(12):2172\u20132179. https:\/\/doi.org\/10.1093\/neuonc\/noac125","journal-title":"Neuro-Oncol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02936-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T20:03:04Z","timestamp":1711310584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02936-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2936"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02936-1","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"17 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}